var data={"title":"Ribavirin (systemic): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ribavirin (systemic): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/791139?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ribavirin-systemic-drug-information\" class=\"drug drug_general\">see &quot;Ribavirin (systemic): Drug information&quot;</a> and <a href=\"topic.htm?path=ribavirin-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ribavirin (systemic): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623465\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate use (oral):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Ribavirin monotherapy is not effective for the treatment of chronic hepatitis C virus (HCV) infection and should not be used alone for this indication.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hemolytic anemia (oral):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The primary clinical toxicity of ribavirin is hemolytic anemia, which may result in worsening of cardiac disease and lead to fatal and nonfatal myocardial infarctions (MIs). Do not treat patients with a history of significant or unstable cardiac disease with ribavirin.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pregnancy (oral):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to ribavirin. In addition, ribavirin has a multiple-dose half-life of 12 days, and it may persist in nonplasma compartments for as long as 6 months. Therefore, ribavirin therapy is contraindicated in women who are pregnant and in the male partners of women who are pregnant. Extreme care must be taken to avoid pregnancy during therapy and for 6 months after completion of treatment in women receiving ribavirin therapy and female partners of men who are taking ribavirin therapy. At least 2 reliable forms of effective contraception must be used during treatment and during the 6-month posttreatment follow-up period.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623473\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Copegus [DSC];</li>\n      <li>Moderiba;</li>\n      <li>Moderiba 1200 Dose Pack;</li>\n      <li>Moderiba 800 Dose Pack;</li>\n      <li>Rebetol;</li>\n      <li>Ribasphere;</li>\n      <li>Ribasphere RibaPak;</li>\n      <li>RibaTab [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623474\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Ibavyr</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45665704\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antihepaciviral, Nucleoside (Anti-HCV)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45665720\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=ribavirin-systemic-drug-information\" class=\"drug drug_general\">see &quot;Ribavirin (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic hepatitis C monoinfection: Note:</b> Children who start treatment prior to age 18 years should continue on pediatric dosing regimen through therapy completion. Recommended therapy duration (manufacturer labeling): Genotypes 2, 3: 24 weeks; all other genotypes: 48 weeks. Consider discontinuation of combination therapy in patients with HCV (genotype 1) at 12 weeks if a 2 log decrease in HCV-RNA has not been achieved or if HCV-RNA is still detectable at 24 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsule or oral solution (Rebetol, Ribasphere) in combination with pegylated or nonpegylated interferon alfa-2b: <b>Note:</b> Oral solution should be used in children &lt;47 kg or those unable to swallow capsules.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Children &ge;3 years and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;47 kg: 15 mg/kg/day in 2 divided doses as oral solution</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">47 to 59 kg: 400 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">60 to 73 kg: 400 mg in the morning; 600 mg in the evening</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;73 kg: 600 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">AAP recommendations: Children &ge;3 years and Adolescents: Oral: <b>Note:</b> Use in combination with interferon alfa-2b (<i>Red Book</i> [AAP] 2012):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&lt;25 kg: 15 mg/kg/day in 2 divided doses as oral solution</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">25 to 36 kg: 200 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;36 to 49 kg: 200 mg in the morning; 400 mg in the evening</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;49 to 61 kg: 400 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;61 to 75 kg: 400 mg in the morning; 600 mg in the evening</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;75 kg: 600 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">AASLD recommendations (Ghany 2009): Children &ge;2 years and Adolescents: Oral: 15 mg/kg/day in 2 divided doses in combination with weekly peginterferon alfa-2b for 48 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">NASPGHAN recommendations (Mack 2012): Children &ge;3 years and Adolescents: Oral: 15 mg/kg/day in 2 divided doses in combination with weekly peginterferon alfa-2a <b>or</b> 2b; duration is either 24 weeks (genotypes 2 or 3) or 48 weeks (genotypes 1 or 4)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablets (Copegus) in combination with peginterferon alfa-2a: Children &ge;5 years and Adolescents: Oral: <b>Note:</b> Assess child's ability to swallow tablet.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">23 to 33 kg: 200 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">34 to 46 kg: 200 mg in the morning; 400 mg in the evening</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">47 to 59 kg: 400 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">60 to 74 kg: 400 mg in the morning; 600 mg in the evening</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;75 kg: 600 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic hepatitis C coinfection with HIV: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;3 years (DHHS [pediatric] 2013): Oral: <b>Note:</b> Use in combination with peginterferon alfa-2a <b>or</b> 2b; recommended therapy duration: 48 weeks, regardless of genotype</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-based dosing: 15 mg/kg/day in 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fixed dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">25 to 36 kg: 200 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;36 to 49 kg: 200 mg in morning; 400 mg in evening</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;49 to 61 kg: 400 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;61 to 75 kg: 400 mg in the morning; 600 mg in the evening</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;75 kg: 600 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents (DHHS [adult] 2013): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Genotype 1: Use in combination with peginterferon alfa-2a <b>or</b> 2b &plusmn; boceprevir <b>or</b> telaprevir (based on antiretroviral therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;75 kg: 400 mg in the morning, 600 mg in the evening for 48 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;75 kg: 600 mg twice daily 48 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Genotype, all others: 400 mg twice daily in combination with peginterferon alfa-2a <b>or</b> 2b for 48 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic hepatitis C monoinfection (in combination with peginterferon alfa-2b):</b> Oral capsule, oral solution (Rebetol, Ribasphere): <b>Note:</b> Recommended therapy duration [manufacturer labeling]: Genotype 1: 48 weeks; genotypes 2, 3: 24 weeks; recommended therapy duration for patients who previously failed therapy: 48 weeks (regardless of genotype)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;66 kg: 400 mg in the morning and evening</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">66 to 80 kg: 400 mg in the morning, 600 mg in the evening</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">81 to 105 kg: 600 mg in the morning, 600 mg in the evening</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&gt;105 kg: 600 mg in the morning, 800 mg in the evening</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic hepatitis C monoinfection (in combination with interferon alfa-2b):</b> Oral capsule (Rebetol, Ribasphere): <b>Note:</b> Individualized therapy duration [manufacturer labeling] 24 to 48 weeks:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&le;75 kg: 400 mg in the morning; 600 mg in the evening</p>\n    <p style=\"text-indent:-4em;margin-left:6em;\">&gt;75 kg: 600 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic hepatitis C monoinfection (in combination with peginterferon alfa-2a):</b> Oral tablet (Copegus, Moderiba, Ribasphere):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genotype 1, 4:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;75 kg: 1,000 mg daily in 2 divided doses for 48 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;75 kg: 1,200 mg daily in 2 divided doses for 48 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genotype 2, 3: 800 mg daily in 2 divided doses for 24 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic hepatitis C coinfection with HIV (in combination with peginterferon alfa-2a):</b> Oral tablet (Copegus, Moderiba, Ribasphere): 800 mg daily in 2 divided doses for 48 weeks (regardless of genotype)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in renal impairment: Chronic hepatitis C infection:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsules/solution (Rebetol, Ribasphere):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;3 years and Adolescents: Serum creatinine &gt;2 mg/dL: Permanently discontinue treatment</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;3 years, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;50 mL/minute: No dosage adjustments are recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;50 mL/minute: Use is contraindicated</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablets:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderiba, Ribasphere: Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;50 mL/minute: No dosage adjustments are recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;50 mL/minute: Use is contraindicated</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Copegus: Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &gt;50 mL/minute: No dosage adjustments are recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 30 to 50 mL/minute: Alternate 200 mg and 400 mg every other day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;30 mL/minute: 200 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ESRD requiring hemodialysis: 200 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <b>Note:</b> The dose of Copegus should not be further modified in patients with renal impairment. If severe adverse reactions or laboratory abnormalities develop it should be discontinued, if appropriate, until the adverse reactions resolve or decrease in severity. If abnormalities persist after restarting, therapy should be discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: Chronic hepatitis C infection:</b> Hepatic decompensation (Child-Pugh class B and C): Children, Adolescents, and Adults: Use is contraindicated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for toxicity:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Children and Adolescents: Once a laboratory abnormality or clinical adverse event has resolved, the ribavirin dose may be increased, based on clinical judgment, to its original assigned dose. Initiate restart at 50% of the full dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Patient <b><span style=\"text-decoration: underline\">without</span></b> cardiac history: </i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemoglobin 8.5 to &lt;10 g/dL:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsules, oral solution: Children &ge;3 years and Adolescents: Decrease ribavirin dose to 12 mg/kg/day; may further reduce to 8 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablets: Children &ge;5 years: Copegus:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">23 to 33 kg: Decrease dose to 200 mg daily (in the morning)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">34 to 59 kg: Decrease dose to 400 mg/day (200 mg twice daily)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;60 kg: Decrease dose to 600 mg/day (200 mg in the morning and 400 mg in the evening)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemoglobin &lt;8.5 g/dL: Children and Adolescents: Oral capsules, solution, tablets: Permanently discontinue ribavirin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">WBC &lt;1,000 mm<sup>3</sup>, neutrophils &lt;500 mm<sup>3</sup>: Children and Adolescents: Oral capsules, solution: Permanently discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Platelets &lt;50 x 10<sup>9</sup>/L: Children and Adolescents: Oral capsules, solution: Permanently discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Patient <b><span style=\"text-decoration: underline\">with</span></b> cardiac history: </i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemoglobin decrease &ge;2 g/dL in any 4-week period of treatment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsules, oral solution: Children &ge;3 years and Adolescents: Decrease by 200 mg daily (regardless of the patient&rsquo;s initial dose); monitor and evaluate weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablets: Children &ge;5 years and Adolescents: Copegus:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">23 to 33 kg: Decrease dose to 200 mg daily (in the morning)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">34 to 59 kg: Decrease dose to 400 mg/day (200 mg twice daily)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;60 kg: Decrease to 600 mg/day (200 mg in the morning, 400 mg in the evening)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemoglobin &lt;12 g/dL after 4 weeks of reduced dose: Children &ge;3 years and Adolescents: Capsules, oral solution, tablets: Permanently discontinue ribavirin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemoglobin &lt;8.5 g/dL: Children and Adolescents: Oral capsules, solution, tablets: Permanently discontinue ribavirin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">WBC &lt;1,000 mm<sup>3</sup>, neutrophils &lt;500 mm<sup>3</sup>: Children and Adolescents: Oral capsules, solution: Permanently discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Platelets &lt;50 x 10<sup>9</sup>/L: Children and Adolescents: Oral capsules, solution: Permanently discontinue treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623546\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rebetol: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ribasphere: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rebetol: 40 mg/mL (100 mL) [contains propylene glycol, sodium benzoate; bubble-gum flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Copegus: 200 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Moderiba: 200 mg [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Moderiba 1200 Dose Pack: 600 mg [contains fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Moderiba 800 Dose Pack: 400 mg [contains fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ribasphere: 200 mg [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ribasphere: 400 mg, 600 mg [contains fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ribasphere RibaPak: Ribasphere RibaPak 800: 400 mg AM dose, 400 mg PM dose, Ribasphere RibaPak 1200: 600 mg AM dose, 600 mg PM dose [contains fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">RibaTab: 400 mg [DSC], 600 mg [DSC] [contains fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 200 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Therapy Pack, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Moderiba: 400 mg &amp; 600 mg (56 ea) [contains fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Moderiba: 200 mg &amp; 400 mg (56 ea) [contains fd&amp;c blue #1 aluminum lake, fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ribasphere RibaPak: Ribasphere RibaPak 1000: 600 mg AM dose, 400 mg PM dose (14 ea, 56 ea) [contains fd&amp;c blue #1 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ribasphere RibaPak: Ribasphere RibaPak 600: 200 mg AM dose, 400 mg PM dose (14 ea, 56 ea) [contains fd&amp;c blue #1 aluminum lake, fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">RibaTab: 400 mg &amp; 600 mg (56 ea [DSC]) [contains fd&amp;c blue #1 aluminum lake]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623476\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623469\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Copegus: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088576.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRl5sCTY8iremx3rqidHKRndg==&amp;TOPIC_ID=105701\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088576.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Moderiba<a target=\"_blank\" href=\"http://dailymed.nlm.nih.gov/dailymed/medguide.cfm?setid=7046ff4c-8a75-5fd4-d40f-ff0cc84eed5f&amp;token=Ox8NWL1nw5Lc6xz8TuSKbf4N6AowF/alCKa//4yo7UiiN2zV8CL7z8z6A5fU0CsA0dLwzFmIuuiYBf6GDrB7mapUQwByGagryVMkGGwcclLl7k3m9f8+dSjDKy+DM7zQ&amp;TOPIC_ID=105701\" target=\"_blank\">http://dailymed.nlm.nih.gov/dailymed/medguide.cfm?setid=7046ff4c-8a75-5fd4-d40f-ff0cc84eed5f</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Rebetol: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089017.pdf%20&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRlbX+CazZqRnnqDwsutGcTINAM2E3lciGdEloCfwEScok=&amp;TOPIC_ID=105701\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm089017.pdf </a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ribasphere: http://kadmon.com/files/ribasphere-cap-pi.pdf</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45665710\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Capsule: Administer with food. Capsule should not be opened, crushed, chewed, or broken.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Solution: Administer with food. Use oral solution for children &lt;47 kg, or those who cannot swallow capsules.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tablet: Administer with food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49133432\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623507\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Oral: Store at 25&deg;C (77&deg;F); excursions permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). Solution may also be refrigerated at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45665705\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule and solution (Rebetol, Ribasphere): Treatment of chronic hepatitis C (in combination with interferon alfa-2b [pegylated or nonpegylated]) in patients with compensated liver disease (FDA approved in ages &ge;3 years and adults). Patients likely to fail retreatment after a prior failed course include previous nonresponders, those who received previous pegylated interferon treatment, patients who have significant bridging fibrosis or cirrhosis, and those with genotype 1 infection. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablets: Treatment of chronic hepatitis C [in combination with peginterferon alfa-2a] in previously untreated patients with compensated liver disease (Copegus: FDA approved in ages &ge;5 years and adults; Moderiba, Ribasphere: FDA approved in ages &ge;18 years and adults); treatment of chronic hepatitis C in patients coinfected with HIV (All tablets: FDA approved in adults). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623466\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Ribavirin may be confused with riboflavin, rifAMPin, Robaxin</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623496\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Clinical trials were conducted in patients receiving Peg Intron or Intron A, and it is not possible to correlate frequency of adverse events with ribavirin alone. Moreover, ribavirin monotherapy is not an effective treatment for chronic hepatitis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac disease, chest pain, flushing, myocardial infarction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Agitation, anxiety, chills (more common in adults), depression (severe), dizziness, emotional lability, fatigue (more common in adults), headache, homicidal ideation, insomnia, irritability (more common in adults), lack of concentration, malaise, memory impairment, mood changes, nervousness, nervousness, pain, right upper quadrant pain, rigors, suicidal ideation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, dermatitis, diaphoresis, eczema, erythema multiforme, erythroderma, pruritus, skin rash, vesicobullous reaction, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Growth suppression (children and adolescents), hypothyroidism, menstrual disease, weight loss (more common in children and adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, colitis, constipation, decreased appetite (children and adolescents), diarrhea, dysgeusia, dyspepsia, gastrointestinal disease (children and adolescents), liver decompensation, nausea (more common in adults), pancreatitis, upper abdominal pain (children and adolescents), xerostomia, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, neutropenia, decreased platelet count, lymphocytopenia, hemolytic anemia, leukopenia, thrombocytopenia, bone marrow depression, pancytopenia, sarcoidosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatomegaly</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Autoimmune disease, exacerbation of sarcoidosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Fungal infection, severe infection, viral infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Erythema at injection site (children and adolescents), inflammation at injection site, injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, musculoskeletal pain (more common in children and adolescents), myalgia (more acommon in adults), weakness (more acommon in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision, conjunctivitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough, dyspnea, pharyngitis, rhinitis, sinusitis, dyspnea on exertion, Flu-like symptoms (more common in children and adolescents), pneumonia, pneumonitis, pulmonary complications, pulmonary infiltrates</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Drug tolerance, Fever (more common in children and adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Aplastic anemia, auditory impairment, bacterial infection, dehydration, diabetes mellitus, graft rejection, hearing loss, pulmonary hypertension, pure red cell aplasia, relapse of drug dependence, retinal detachment, Stevens-Johnson syndrome, toxic epidermal necrolysis, vertigo</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623491\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Oral formulations: Hypersensitivity to ribavirin or any component of the formulation; women who are pregnant or may become pregnant; males whose female partners are pregnant; patients with hemoglobinopathies (eg, thalassemia major, sickle cell anemia); concomitant use with didanosine</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Ribasphere capsules and Rebetol capsules/solution: Additional contraindications: Patients with a CrCl &lt;50 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Oral combination therapy with alfa interferons: Autoimmune hepatitis, hepatic decompensation (Child-Pugh score &gt;6; class B and C) in cirrhotic chronic hepatitis C monoinfected patients prior to treatment, hepatic decompensation (Child-Pugh score &ge;6) in cirrhotic chronic hepatitis C patients coinfected with HIV prior to treatment. Also refer to individual monographs for Interferon Alfa-2b (Intron A), Peginterferon Alfa-2b, and Peginterferon Alfa-2a (Pegasys) for additional contraindication information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623492\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hemolytic anemia: <b>[US Boxed Warning]: Hemolytic anemia is the primary clinical toxicity of oral therapy; anemia associated with ribavirin may worsen underlying cardiac disease and lead to fatal and nonfatal myocardial infarctions. Avoid use in patients with significant/unstable cardiac disease.</b> Anemia usually occurs within 1 to 2 weeks of therapy initiation; observed in ~10% to 13% of patients when alfa interferons were combined with ribavirin. Assess cardiac function before initiation of therapy. If patient has underlying cardiac disease, assess electrocardiogram prior to and periodically during treatment. If any deterioration in cardiovascular status occurs, discontinue therapy. Use caution in patients with baseline risk of severe anemia. Assess hemoglobin and hematocrit at baseline and, at minimum, weeks 2 and 4 of therapy since initial drop may be significant. Patients with renal dysfunction and/or those &gt;50 years of age should be carefully assessed for development of anemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Risk of hepatic decompensation in chronic hepatitis C patients treated with combination therapy; monitor hepatic function closely and discontinue therapy immediately if evidence of hepatic decompensation is observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatitis C: Appropriate use: <b>[US Boxed Warning]: Ribavirin monotherapy is not effective for chronic hepatitis C infection and should not be used alone for hepatitis C.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment or discontinuation may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Combination therapy with alfa interferons: </i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autoimmune/infectious disorders: Have occurred with combination therapy; use with caution in patients with autoimmune disease or severe infection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Pancytopenia has occurred with combination therapy and concomitant use of azathioprine; onset occurs within 3 to 7 weeks; discontinue combination therapy and azathioprine if pancytopenia occurs; may be reversible (usually within 4 to 6 weeks).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dental and periodontal disorders: Have been reported with combination therapy; patients should be instructed to brush teeth twice daily and have regular dental exams. Xerostomia may contribute to and/or exacerbate dental disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic reactions: Severe cutaneous reactions, including Stevens-Johnson syndrome and exfoliative dermatitis have been reported (rarely) with combination therapy; discontinue immediately with signs or symptoms of severe skin reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Has occurred with combination therapy; monitor blood sugars closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Acute hypersensitivity reactions (eg, anaphylaxis, angioedema, bronchoconstriction, and urticaria) have been observed with combination therapy; discontinue immediately with signs or symptoms of severe hypersensitivity reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ophthalmologic disorders: Serious disorders (eg, retinopathy, macular edema, retinal artery/vein thrombosis, optic neuritis, retinal detachment) have occurred with combination therapy. All patients require an eye exam at baseline; those with preexisting ophthalmologic disorders (eg, diabetic or hypertensive retinopathy) require periodic follow up. Discontinue therapy in patients with new or worsening ophthalmologic disorders.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: Has occurred with combination therapy; interrupt therapy if pancreatitis is suspected and discontinue if confirmed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric disorders: Severe psychiatric events have occurred including depression and suicidal/homicidal ideation during combination therapy. Suicidal ideation or attempts occurred more often in pediatric patients versus reports in adults during treatment and off-therapy follow-up (2.4% vs 1%). Avoid use in patients with a psychiatric history; discontinue if severe psychiatric symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary events: Pulmonary symptoms (eg, dyspnea, pulmonary infiltrates, pneumonitis, pneumonia [rarely fatal]) have been associated with combination therapy; use with caution in patients with pulmonary disease, including sarcoidosis (exacerbation reported).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; may be more susceptible to adverse effects such as anemia. Monitor renal function closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: In combination therapy with alfa interferons, ribavirin may cause a reduction in growth velocity in pediatric patients for the length of treatment. Delay in weight and height increases have been noted in children treated with combination therapy. In clinical studies, decreases were noted in weight and height for age z-scores and normative growth curve percentiles. Following treatment, rebound growth and weight gain occurred in most patients; however, a small percentage did not. Long-term data indicate that combination therapy may inhibit growth resulting in reduced adult height. Growth should be closely monitored in pediatric patients during therapy and post-treatment for growth catch-up.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: <b>[US Boxed Warning]: Significant teratogenic and/or embryocidal effects have been observed in all animal studies. Use is contraindicated in pregnant women or male partners of pregnant women. Avoid pregnancy in female patients and female partners of male patients during therapy by using two effective forms of contraception; continue contraceptive measures for at least 6 months after completion of therapy.</b> The manufacturer recommends that pregnant health care workers take precautions to limit exposure to ribavirin aerosol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Safety and efficacy have not been established in patients who have failed previous interferon therapy, received organ transplants, or been coinfected with hepatitis B or HIV (ribavirin tablets may be used in adult HIV-coinfected patients with clinically stable disease and CD4+ cell count &gt;100 cells/mm<sup>3</sup>). Hemoglobin at initiation must be &ge;12 g/dL (women) or &ge;13 g/dL (men) in CHC monoinfected patients and &ge;11 g/dL (women) or &ge;12 g/dL (men) in CHC and HIV coinfected patients. Oral ribavirin should not be used for adenovirus, RSV, influenza or parainfluenza infections. Combination therapy of peginterferon and ribavirin, <b>without</b> additional HCV antiviral agent(s), is <b>not </b>recommended for the treatment of hepatitis C virus (AASLD/IDSA 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45665716\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Pediatric patients treated with ribavirin in combination with alfa interferon lag behind in height and weight gains compared to normative population growth curves for the duration of treatment. Severe inhibition of growth velocity (&lt;3rd percentile) was reported in 70% of pediatric patients during clinical trials. After therapy, 20% continued to have severely inhibited growth; however, in the majority of patients, growth velocity rates increased such that by 6 months post-treatment, weight gain stabilized to 53rd percentile (similar to predicted based on average baseline weight: 57th percentile) and height gain stabilized to 44th percentile (less than predicted based on average baseline height: 51st percentile). Post-treatment, rebound growth occurred in most patients; however, long-term data indicate that combination therapy may result in reduced adult height in some patients. Growth should be closely monitored in pediatric patients during therapy and post-treatment for growth catch-up. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623501\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623498\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=105701&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AzaTHIOprine: Ribavirin (Systemic) may increase serum concentrations of the active metabolite(s) of AzaTHIOprine. Specifically, concentrations of potentially myelotoxic methylated metabolites may be increased, while concentrations of active 6-thioguanine nucleotides may be decreased.  Management: Consider using alternative agent(s) when possible.  When these drugs are used in combination, monitor patients closely for signs/symptoms of myelosuppression.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Didanosine: Ribavirin (Systemic) may enhance the adverse/toxic effect of Didanosine. Ribavirin (Systemic) may increase serum concentrations of the active metabolite(s) of Didanosine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Influenza Virus Vaccine (Live/Attenuated): Antiviral Agents (Influenza A and B) may diminish the therapeutic effect of Influenza Virus Vaccine (Live/Attenuated).  Management: Avoid anti-influenza antivirals during the period beginning 48 hours prior to and ending 2 weeks after vaccine administration.  Persons receiving these agents within 2 weeks of the live intranasal spray vaccine should receive a repeat vaccine dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Interferons (Alfa): May enhance the adverse/toxic effect of Ribavirin (Systemic). Hemolytic anemia has been observed.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Ribavirin (Systemic) may diminish the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine: May enhance the adverse/toxic effect of Ribavirin (Systemic). Specifically, the risk/severity of anemia may be increased. Management: Due to significantly increased risk of anemia, consider even closer monitoring for anemia than routinely recommended for ribavirin. Alternative therapies should be considered when clinically possible, particularly for patients with other risk factors.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623506\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">High-fat meal increases the AUC and C<sub>max</sub>. Management: Capsule (in combination with peginterferon alfa-2b) and tablet should be administered with food. Other dosage forms and combinations should be taken consistently in regards to food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623487\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623488\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>[US Boxed Warning]: Use is contraindicated in pregnant women or male partners of pregnant women. Significant teratogenic and/or embryocidal effects have been observed in all animal species with adequate studies. Avoid pregnancy in female patients and female partners of male patients during therapy by using two effective forms of contraception; continue contraceptive measures for at least 6 months after completion of therapy.</b> A negative pregnancy test is required immediately before initiation, monthly during therapy, and for 6 months after treatment is discontinued. If patient or female partner becomes pregnant during treatment, she should be counseled about potential risks of exposure.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Mother-to-child transmission of HCV does not occur if the woman is not viremic, therefore, HCV-infected women of childbearing potential should postpone pregnancy until therapy is complete. Treatment of HCV is not recommended for women who are already pregnant (AASLD/IDSA 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers and patients are encouraged to enroll women exposed to ribavirin during pregnancy or within 6 months after treatment in the Ribavirin Pregnancy Registry (800-593-2214).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45665711\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Oral: Pretreatment hematological and biochemical tests are recommended for all patients; dental exam, ECG (if preexisting cardiac abnormalities or disease) and ophthalmic exam (also periodically during treatment for those with preexisting ophthalmologic disorders) are also recommended. In adults, hematologic tests should be at treatment weeks 2 and 4, biochemical tests at week 4, and TSH at week 12. In pediatric patients, monitor growth closely during and after treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Pregnancy screening (in woman of childbearing age) and pregnancy tests monthly during and for 6 months after treatment discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">In pediatric clinical studies, hematologic and biochemical assessments were made at weeks 1, 3, 5 and 8, then every 4 weeks thereafter. Growth velocity and weight should also be monitored during and periodically after treatment discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Baseline values used in adult clinical trials in combination with alfa interferons: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Platelet count &ge;90,000/mm<sup>3</sup> (75,000/mm<sup>3</sup> for cirrhosis or 70,000/mm<sup>3</sup> for coinfection with HIV) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ANC &ge;1500/mm<sup>3</sup></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hemoglobin &ge;12 g/dL for women and &ge;13 g/dL for men (11 g/dL for HIV coinfected women and 12 g/dL for HIV coinfected men)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">TSH and T<sub>4</sub> within normal limits or adequately controlled </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CD4<sup>+</sup> cell count &ge;200 cells/microL or CD4<sup>+</sup> cell count 100 to 200 cells/microL and HIV-1 RNA &lt;5,000 copies/mL for coinfection with HIV </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Serum HCV RNA (pretreatment, week 12 and week 24, and 24 weeks after completion of therapy). <b>Note:</b> Discontinuation of therapy may be considered after 12 weeks in patients with HCV (genotypes 1,4) who fail to achieve an early virologic response (EVR) (defined as &ge;2-log decrease in HCV RNA compared to pretreatment) or after 24 weeks with detectable HCV RNA. Treat patients with HCV (genotypes 2,3) for 24 weeks (if tolerated) and then evaluate HCV RNA levels (Ghany 2009). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623511\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits replication of RNA and DNA viruses; inhibits influenza virus RNA polymerase activity and inhibits the initiation and elongation of RNA fragments resulting in inhibition of viral protein synthesis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623514\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Oral capsule: Single dose: V<sub>d</sub>: 2,825 L; distribution significantly prolonged in the erythrocyte (16 to 40 days), which can be used as a marker for intracellular metabolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Oral: None</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatically and intracellularly (forms active metabolites); may be necessary for drug action</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: 64%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination, plasma: Adults: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Capsule, single dose: 24 hours in healthy adults, 44 hours with chronic hepatitis C infection (increases to ~298 hours at steady state)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tablet, single dose: ~120 to 170 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral capsule: Multiple doses: Children and Adolescents 3 to 16 years: ~2 hours; Adults: 3 hours; Tablet: 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Oral capsule: Urine (61%), feces (12%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45623548\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Rebetol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (70): $741.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Ribasphere Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (84): $394.13</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Ribavirin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (84): $800.19</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Rebetol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/mL (100 mL): $232.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Therapy Pack</b> (Moderiba Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 &amp; 400 mg (56): $876.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 &amp; 600 mg (56): $1,153.37</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Therapy Pack</b> (Ribasphere RibaPak Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 &amp; 400 mg (14): $427.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 &amp; 600 mg (14): $562.27</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Moderiba 1200 Dose Pack Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (56): $1,384.02</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Moderiba 800 Dose Pack Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (56): $922.68</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Moderiba Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (168): $474.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ribasphere Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (168): $474.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (56): $1,799.23</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (56): $2,698.85</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ribasphere RibaPak Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">400 mg (14): $449.81</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (14): $674.71</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ribavirin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (168): $1,390.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45855028\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Copeg (BD);</li>\n      <li>Copegus (AE, AR, AT, AU, BB, BE, BG, BH, CH, CL, CO, CY, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, HK, HR, HU, IE, IL, IS, IT, JO, JP, KW, LB, LT, LU, LV, MX, MY, NL, NO, PL, PT, QA, RO, SA, SE, SG, SI, SK, TH, TR, UY, ZA);</li>\n      <li>Desiken (MX);</li>\n      <li>Hanavizin (VN);</li>\n      <li>Hepaviral (ID);</li>\n      <li>Ibavyr (AU, NZ);</li>\n      <li>Livel (UA);</li>\n      <li>Moderiba (DK, EE, FI, IE, LT, LV);</li>\n      <li>Opegus (BD);</li>\n      <li>Rebetol (AE, AT, AU, BB, BE, BH, BR, CH, CL, CO, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, ID, IE, IL, IN, IS, IT, JO, JP, LB, LT, MT, MY, NL, NO, NZ, PH, PL, PT, QA, RO, SE, SG, SI, SK, TR, VE, VN);</li>\n      <li>Riavirin (QA);</li>\n      <li>Ribacee (BD);</li>\n      <li>Ribarin (BD);</li>\n      <li>Ribavin (IN, LB);</li>\n      <li>Ribazole (VN);</li>\n      <li>Riboflax (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Rui Di (CN);</li>\n      <li>Rybaryn (UA);</li>\n      <li>Trivorin (MX);</li>\n      <li>Varinar (MX);</li>\n      <li>Vilona (MX);</li>\n      <li>Virazide (CR, DO, GT, HN, ID, IN, MX, NI, PA, PK, SV);</li>\n      <li>Xilopar (AR);</li>\n      <li>Zyverin (LK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. <i>Red Book: 2012 Report of the Committee on Infectious Diseases</i>. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ribavirin-systemic-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Copegus (ribavirin tablet, film coated) [prescribing information]. South San Francisco,CA: Genentech USA Inc; February 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS. Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations From the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a>. November 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections (OI) in HIV-Infected Adults and Adolescents, &quot;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations from the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA),&quot; May 7, 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ghany MG, Strader DB, Thomas DL, et al, &ldquo;Diagnosis, Management And Treatment Of Hepatitis C: An Update,&rdquo; <i>Hepatology</i>, 2009, 49(4):1335-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ribavirin-systemic-pediatric-drug-information/abstract-text/19330875/pubmed\" target=\"_blank\" id=\"19330875\">19330875</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Janai HK, Marks MI, Zaleska M, et al, &ldquo;Ribavirin: Adverse Drug Reactions 1986 to 1988,&rdquo; <i>Pediatr Infect Dis J</i>, 1990, 9(3):209-11. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ribavirin-systemic-pediatric-drug-information/abstract-text/2139930/pubmed\" target=\"_blank\" id=\"2139930\">2139930</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mack CL, Gonzalez-Peralta RP, Gupta N, et al. NASPGHAN practice guidelines: diagnosis and management of hepatitis C infection in infants, children, and adolescents. <i>J Pediatr Gastroenterol Nutr</i>. 2012;54(6):838-855.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ribavirin-systemic-pediatric-drug-information/abstract-text/22487950/pubmed\" target=\"_blank\" id=\"22487950\">22487950</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moderiba (ribavirin) [prescribing information]. North Chicago, IL: AbbiVie Inc; February 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;NIH Consensus Statement on Management of Hepatitis C: 2002,&rdquo; <i>NIH Consens State Sci Statements</i>, 2002, 19(3):1-46. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ribavirin-systemic-pediatric-drug-information/abstract-text/14768714 /pubmed\" target=\"_blank\" id=\"14768714 \">14768714 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rebetol (ribavirin) [prescribing information]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme Corp; May 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ribasphere capsules (ribavirin) [prescribing information]. Greenville,NC: DSM Pharmaceuticals Inc; December 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ribasphere tablets (ribavirin) [prescribing information]. Kenilworth, NJ: Schering Corporation; April 2011. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ribavirin-systemic-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wirth S, Lang T, Gehring S, et al, &ldquo;Recombinant Alfa-Interferon Plus Ribavirin Therapy in Children and Adolescents With Chronic Hepatitis C,&rdquo; <i>Hepatology</i>, 2002, 36(5):1280-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ribavirin-systemic-pediatric-drug-information/abstract-text/12395341/pubmed\" target=\"_blank\" id=\"12395341\">12395341</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 105701 Version 48.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F45623465\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F45623473\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F45623474\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F45665704\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F45665720\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F45623546\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F45623476\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F45623469\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F45665710\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49133432\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F45623507\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F45665705\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F45623466\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F45623496\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F45623491\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F45623492\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F45665716\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F45623501\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F45623498\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F45623506\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F45623487\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F45623488\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F45665711\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F45623511\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F45623514\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F45623548\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F45855028\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/105701|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ribavirin-systemic-drug-information\" class=\"drug drug_general\">Ribavirin (systemic): Drug information</a></li><li><a href=\"topic.htm?path=ribavirin-systemic-patient-drug-information\" class=\"drug drug_patient\">Ribavirin (systemic): Patient drug information</a></li></ul></div></div>","javascript":null}